A protein called SOX11 helps spinal cord glioma cells grow
Original title: H3K27me3 loss and METTL3-m6A converge to upregulate SOX11/SMARCA4 and drive H3K27-altered spinal cord glioma stemness and proliferation.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done in animals, not people. Most findings at this stage never become treatments.
This was only done in lab cells and animals, not in people.
The short version
Lab tests found a protein that helps these tumor cells stay strong and keep growing.
What was studied. Researchers used tumor cells taken from people with spinal cord H3 K27-altered: A change in a histone, one of the proteins that DNA wraps around. When a diffuse glioma has it, and sits in the middle of the brain or spine, it is called a diffuse midline glioma. See the glossary glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary. They grew the cells in the lab and also tested them in animals.
What they found. Two changes inside the cells worked together to raise a protein called SOX11. SOX11 joined with another protein, SMARCA4, to keep the cells growing and stem-like. In patient tumors, high SOX11 went along with faster growth and worse outcomes. Those tumors also responded more to a drug that blocks SMARCA4.
What this means, and what it doesn't
What it could mean: SOX11 may one day be a sign of how a tumor will behave. It may also point to a target for new drugs to study.
What it doesn't mean: This is early lab and animal work. No patients were treated with this drug here. It is not a treatment you can ask for now, and it is not a cure. It does not change the care you get today. Years of testing in people would be needed first.
Source: PubMed, September 28, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.